The Global Canine Influenza Vaccine Market Primed to Grow at a Robust Pace due to Rising Pet Adoption

on
Global Canine Influenza Vaccine Market 

The global canine influenza vaccine market provides immunity against canine influenza, which is a highly contagious respiratory infection found in dogs. Canine influenza vaccines offer protection for pet dogs against multiple strains of canine flu virus that are circulating. Rising pet adoption around the world along with increasing awareness about pet healthcare management have boosted the demand for canine flu vaccines over the years.

The Global canine influenza vaccine market is estimated to be valued at US$ 2,562.1 Mn in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the Global Canine Influenza Vaccine Market Size are Zoetis Services LLC, Merck & Co., Inc., Covetrus, CSL Limited, Boehringer Ingelheim Animal Health USA Inc., and Elanco. Strong research and development activities by major players coupled with strategic collaborations for vaccine development are helping them strengthen their market presence.

The global market provides significant opportunities for players involved in development and commercialization of modified live vaccines as the currently available canine influenza vaccines are inactivated ones. Major players are focusing their efforts on novel vaccine development to provide longer lasting immunity.

Geographical expansion into emerging Asian and Latin American markets with growing pet ownership and increasing per capita pet healthcare spending is another area global players are targeting for future growth. Investments into vaccination awareness programs in these regions can potentially open new revenue streams.

Market drivers: Rising pet adoption globally along with growing awareness about importance of pet vaccination is a key driver facilitating the growth of canine influenza vaccine market. Pet owners understanding the signs of canine flu infection and its potential threat to other pets in close vicinity has augmented the demand for flu vaccination.

Market restrain: High costs involved in research and development of new generation vaccines along with stringent regulatory approvals are some of the factors restraining fast paced market growth. Vaccine development against evolving flu strains also needs continuous investments limiting commercial returns in short term.

Segment Analysis
The live attenuated segment currently holds the largest share of the global canine influenza vaccine market. Live attenuated vaccines are attenuated versions of flu viruses that have been adapted to grow safely in chicken eggs or cell cultures. They cause a mild infection and stimulate a good immune response. This provides more broad and longer lasting immunity compared to killed or inactive vaccines. Therefore, live attenuated vaccines are preferred by most veterinarians and account for the highest revenue share at present.

The recombinant canine influenza vaccines segment is projected to witness the highest growth over the forecast period. Recombinant vaccines use a selected gene from the flu virus that codes for a protein known to stimulate antibody production. This eliminates the need to grow the live virus and reduces the chance of unplanned mutations. They produce fewer side effects in dogs and offer durable protection against different virus strains. With advancements in recombinant DNA technology, more accurate and safer influenza vaccines can be developed, thereby boosting the adoption of recombinant vaccines.

Global Analysis
The North American region currently dominates the global canine influenza vaccine market. This is attributed to growing pet care expenditure, rising dog population, and increased awareness about canine diseases among pet owners in countries like the United States and Canada. Veterinary healthcare is also well-established in North America with ease of access.

The Asia Pacific region is expected to grow at the fastest pace during the forecast period. Rapid growth in companion animal adoption, improving pet healthcare infrastructure, and rising per capita income in developing countries are driving the regional market. Additionally, increasing awareness about preventive care for pets and availability of low-cost generic vaccines will support the Asia Pacific canine influenza vaccine market over the coming years.

Comments

Post a Comment